³í¹®) Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer
¿¬¼¼´ëÇб³ °³²¼¼ºê¶õ½ºº´¿ø(º´¿øÀå ¼Û¿µ±¸) À¯¹æ¿Ü°ú Á¤ÁØ(»çÁø ñ§)·¾È¼º±Í ±³¼ö(éÓ)ÆÀ